Valentina Mey

Medicine · Health Sciences

18h-index1.5kcitations37works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(11), Lung Cancer Treatments and Mutations(11), Cancer therapeutics and mechanisms(11), Lung Cancer Research Studies(6), Cancer Genomics and Diagnostics(5)

Publications37 total

Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
2023Open Access
Data from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
2023Open Access
Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
2023Open Access
Data from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
2023Open Access
Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy.
PubMed·2015· 6 cited
Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer
ACS Medicinal Chemistry Letters·2013· 28 citedOpen Access
Synergistic interaction between <scp>PPAR</scp> ligands and salbutamol on human bronchial smooth muscle cell proliferation
British Journal of Pharmacology·2012· 11 citedOpen Access
Contents
Lung Cancer·2011Open Access
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines
Lung Cancer·2011· 29 cited
Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells
Chemotherapy·2010· 24 cited
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
Cancer Chemotherapy and Pharmacology·2009· 19 citedOpen Access
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer
Cancer Chemotherapy and Pharmacology·2009· 54 cited
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
Molecular Cancer Therapeutics·2009· 39 citedOpen Access
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma
Laboratory Investigation·2008· 40 citedOpen Access
Correlation of <i>CDA, ERCC1</i>, and <i>XPD</i> Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
Clinical Cancer Research·2008· 207 cited
Radiosensitizing potential of small organic molecules toward hypoxic tumor cells in the radiotherapy
CINECA IRIS Institutial research information system (University of Pisa)·2008
D3-06: Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer patients
Journal of Thoracic Oncology·2007Open Access
Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration
Journal of Clinical Oncology·2007
A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge
Cancer Chemotherapy and Pharmacology·2007· 12 cited
242: Pharmacogenetics Determinants of Anticancer Activity of Intravescical Gemcitabine in Patients with Superficial Transitional Cell Carcinoma (TCC) of The Bladder
The Journal of Urology·2007Open Access
page 1 of 2Next →

Frequent Co-authors

Romano Danesi(34), Mario Del Tacca(29), Elisa Giovannetti(26), Sara Nannizzi(25), S Ricciardi(17), Godefridus J. Peters(6), Giuseppe Pasqualetti(6), Francesco Crea(6), Cinzia Orlandini(5), Carmelo Tibaldi(5), Enrico Vasile(5), Alfredo Falcone(5), Filippo Cortesi(5), Mariëlle I. Gallegos Ruiz(5), Ugo Boggi(3), Franco Mosca(3), Francesco Pasqualetti(3), L. Cionini(3), Filippo de Braud(3), I. Stasi(3)